Dr. Reddys Laboratories Ltd.

BSE: 500124 | NSE: DRREDDY
Mid Cap | Pharmaceuticals & Drugs
1368.75
-5.80 (-0.42%)
< Home < Back

Dr Reddy’s signs MoU with Purdue University for drug research and development

Date: 29-07-2015

In order to strengthen pharmaceutical research and development, Dr Reddy’s Laboratories (DRL) has signed a memorandum of Understanding (MoU) with Purdue University. This MoU will  forge a strong strategic partnership in a range of research areas and novel technologies in the field of pharmaceutical processes and product development.

The collaboration will include student engagement and faculty exchanges and may include a site at Purdue Research Park.

Dr Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.